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Opinion statement
Critical limb ischemia (CLI), defined as chronic ischemic rest pain, ulcers, or gangrene
attributable to objectively proven arterial occlusive disease, is the most advanced form
of peripheral arterial disease. Traditionally, open surgical bypass was the only effective
treatment strategy for limb revascularization in this patient population. However,
during the past decade, the introduction and evolution of endovascular procedures
have significantly increased treatment options. In a certain subset of patients for
whom either surgical or endovascular revascularization may not be appropriate, primary
amputation remains a third treatment option. Definitive high-level evidence on which
to base treatment decisions, with an emphasis on clinical and cost effectiveness, is still
lacking. Treatment decisions in CLI are individualized, based on life expectancy, func-
tional status, anatomy of the arterial occlusive disease, and surgical risk. For patients
with aortoiliac disease, endovascular therapy has become first-line therapy for all but
the most severe patterns of occlusion, and aortofemoral bypass surgery is a highly
effective and durable treatment for the latter group. For infrainguinal disease, the
available data suggest that surgical bypass with vein is the preferred therapy for CLI
patients likely to survive 2 years or more, and for those with long segment occlusions
or severe infrapopliteal disease who have an acceptable surgical risk. Endovascular
therapy may be preferred in patients with reduced life expectancy, those who lack
usable vein for bypass or who are at elevated risk for operation, and those with less
severe arterial occlusions. Patients with unreconstructable disease, extensive necrosis
involving weight-bearing areas, nonambulatory status, or other severe comorbidities
may be considered for primary amputation or palliative measures.
Introduction
Lower-extremity peripheral arterial disease (PAD) is
estimated to affect between 8 million and 10 million
Americans [1,2]. This prevalence is expected to in-
crease, not only in the United States, but across the
world as the population ages, cigarette smoking per-
sists, and the epidemic of diabetes mellitus and obesi-
ty grows [2]. Critical limb ischemia (CLI), the most
advanced form of PAD, is associated with a high riskof cardiovascular events, including major limb loss,
myocardial infarction, stroke, and death [1,3–5].
The likelihood of death has been reported to be as high
as 20% within 6 months of CLI diagnosis and surpasses
50% at5yearspostdiagnosis[6,7].Thesehighmortality
rates exceed those seen in any other pattern of occlusive
disease, including patients with symptomatic coronary
arterydisease[8,9],andreflecttheseveresystemiceffects
associated with a diagnosis of CLI.
To date, no pharmacologic or biologic therapy has
demonstrated efficacy in reversing the circulatory im-
pairment seen in patients with CLI. Therefore, if suc-
cessful revascularization is not feasible, impaired
quality of life, limb loss, and death have been the
norm rather than the exception [10•].
The economic impact of this growing burden of
PAD is being experienced acutely in the United States
and many other nations. A study analyzing Medicare
data for 2001 found that $4.37 billion was spent on
PAD-related treatment [2]. In total, PAD-related treat-
ment accounted for approximately 13% of all Medicare
Part A and B expenditures for the PAD-treated cohort,
and2.3%ofallMedicarePart AandBannualspending.
The widespread adoption of endovascular proce-
dures by multiple disciplines has significantly increased
treatment options [6, 11]. This change in treatment par-
adigm has been driven by technological advances, as
well as by the desire of patients and physicians to re-
duce procedural risk, albeit with potential tradeoffs of
inferior durability and greater cost [6]. Between 1996
and 2006, the number of endovascular lower-extremity
interventions in the Medicare population reportedly in-
creased by 230%, whereas the number of bypass proce-
dures decreased by 42% [12].
Despite the enormity of the patient population at
risk and the multiple treatment options available, rig-
orous high-level evidence to support informed clinical
decision making in patients with CLI has been lacking.
There are few high-quality prospective studies and
even fewer randomized controlled clinical trials. In
this review, we attempt to summarize the existing evi-
dence guiding therapeutic decision making in CLI.
Treatment
Diet and lifestyle
& No clinical trials have been conducted, or are ongoing, that specifi-
cally address the role of diet modifications/supplements in the pro-
gression of CLI.
& Lipid abnormalities, including elevated total and low-density lipopro-
tein (LDL) cholesterol, decreased high-density lipoprotein cholesterol,
and hypertriglyceridemia, are strongly associated with lower-extremity
PAD. As a result, low-cholesterol diets have been recommended for
patients with CLI [13].
& Cigarette smoking is a strong predictor of lower-extremity PAD, with
a large number of epidemiologic studies establishing an increased
incidence of PAD in smokers compared with nonsmokers. Further-
more, the severity of PAD tends to increase in a dose-dependent
manner with the number of cigarettes smoked [14]. Interventions
directed at smoking cessation, or decreased usage, are critical
[11,13].
Pharmacologic treatment
& To date, no pharmacologic therapy has demonstrated efficacy in re-
versing the arterial occlusive lesions, or the resulting impaired per-
fusion, seen in patients with CLI. The Circulase trial (Mitsubishi
Pharma Corp, Tokyo, Japan), published in 2006, randomly assigned
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ecraprost (parenteral prostaglandin) or placebo. The study treatment
was found to confer no benefit (or harm) on the primary study end
point, death or amputation above the ankle at 180 days [15].
& Various reports have demonstrated that cardioprotective medications
such as statins, β-blockers, angiotensin-converting enzyme inhibi-
tors, and antiplatelet agents are associated with a decreased cardio-
vascular event rate in patients with PAD [16–21]. However, these
studies have been conducted in heterogeneous populations, not
specifically in patients with CLI. In a retrospective analysis of 1404
CLI patients who had undergone surgical revascularization, statins
were demonstrated to confer a significant survival advantage at 1 year
(hazard ratio [HR] for mortality, 0.71; P=0.03) [22]. However, op-
timum dosing and therapeutic targets (eg, LDL cholesterol, C-reactive
protein levels) for statin therapy in PAD patients are uncertain, and
more clinical trials are needed to determine whether statins have
direct beneficial effects in the peripheral circulation (limb). In gen-
eral, current recommendations for the use of cardioprotective med-
ications in CLI follow published general PAD guidelines [13,19].
Interventional procedures
& Various endoluminal catheter-based devices have been developed for
patients with CLI. These evolving technologies include balloon an-
gioplasty, CryoPlasty therapy (Boston Scientific, Natick, MA), stent/
stent-graft placement, laser atherectomy, and mechanical atherec-
tomy. Beyond single-center case series demonstrating feasibility and
technical success, a paucity of high-level data precludes critical evalua-
tion of these technologies. These results often are difficult to interpret
because of differences in patient selection, use of multiple therapeutic
modalities, and variable end points with variable study durations. A
summary of several of the larger, recent series reporting outcomes of
endovascular treatment for patients with CLI is presented in Table 1.
& The Transatlantic Inter-Society Consensus Document on Manage-
ment of Peripheral Arterial Disease (TASC II), published in 2006, was
developed by an international working group charged with reviewing
the literature and putting forth recommendations for the diagnosis
and treatment of PAD [11]. All recommendations were assigned a
grade based on the level of available evidence to support that recom-
mendation. The working group recommended endovascular therapy as
the first-line treatment method for patients with TASC A and B lesions.
Of note, this recommendation received a grade C for evidence, which
was defined as “…evidence obtained from expert committee reports or
opinions….no applicable studies of good quality”[11].
& The BASIL (Bypass Versus Angioplasty in Severe Ischaemia of the Leg)
trial, sponsored by the UK National Institute of Health Research
Health Technology Assessment program, is the only randomized
controlled trial (RCT) comparing open surgical bypass with
216 Vascular Diseaseendovascular therapy in patients with severe limb ischemia (SLI) due
to infrainguinal disease; therefore, it is worth considering in detail
[6]. The term SLI was used to “admit patients with chronic, poten-
tially limb threatening, ischemia but who did not necessarily have
ankle pressures less than 50 mmHg and thus did not strictly fulfill
the requirements of the term CLI” [6]. It also is important to note
that patients were eligible for BASIL if they were deemed suitable
for either angioplasty or bypass and if they met the investigators’
criterion of “grey area of clinical equipoise.”
& The BASIL trial began enrollment in 1999 and randomly assigned
452 patients from 27 centers across Scotland and England. In 2005,
the BASIL trialists reported an analysis of outcomes out to 2 years—
demonstrating no difference in overall survival or amputation-free
survival by intention-to-treat analysis between surgical bypass and
endovascular therapy, with surgery being more expensive in the short
term [6]. However, post hoc analysis demonstrated that beyond
2 years, patients initially assigned to open bypass surgery had a sig-
nificantly improved amputation-free survival (adjusted HR, 0.37;
95% CI, 0.17–0.77; P=0.008) and reduced all-cause mortality (ad-
justed HR, 0.34; 95% CI, 0.17–0.71; P=0.004) relative to angioplasty
[6]. This finding of the BASIL trial was considered significant enough
to warrant funding of an extension study, the results of which were
Table 1. Recent studies reporting outcomes in patients undergoing endovascular therapy for treatment of
critical limb ischemia
Study Patients, n Study type Outcome measure(s) Event rate, %
Laird et al., 2006 [62] 155 Multicenter series Amputation-free survival (6 mo) 82
Bosiers et al., 2007 [63] 51 Multicenter series Amputation-free survival (1 y) 79
DeRubertis et al., 2008 [64] 184 Single-center series Limb salvage (1 y) 88.3
Primary patency (1 y) 54±5
Primary patency (2 y) 43±7
Giles et al., 2008 [65] 176 Single-center series Freedom from restenosis,
reintervention, or amputation (1 y)
39
Freedom from restenosis,
reintervention, or amputation (2 y)
35
Primary patency (1 y) 53
Primary patency (2 y) 51
Limb salvage (3 y) 84
Survival (1 y) 81
Survival (3 y) 54
Romiti et al., 2008 [66] – Meta-analysis Primary patency (1 y) 58.1±4.6
Primary patency (3 y) 48.6±8.0
Secondary patency (1 y) 68.2±5.9
Secondary patency (3 y) 62.9±11.0
Limb salvage (1 y) 86.0±2.7
Limb salvage (3 y) 82.4±3.4
Survival (1 y) 87.0±2.1
Survival (3 y) 68.4±5.5
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period (mean follow-up, 3.1 years; range, 1–5.7 years), there was no
significant difference in overall survival or amputation-free survival by
intention-to-treat analysis. However, for patients surviving to 2 years
post procedure (70% of the study cohort), initial randomization to
open bypass was associated with significantly improved overall sur-
vival (mean gain of 7.3 months; P=0.02) and a trend toward increased
amputation-free survival (mean gain of 5.9 months; P=0.06). The
investigators also published the trial outcomes using an as-treated
analysis [25•], an approach that accounts for early treatment cross-
overs but, importantly, sacrifices the power of randomization. In this
analysis, they found that among patients assigned to open surgery,
those who received prosthetic grafts (25% of the surgical group) ex-
perienced reduced amputation-free survival compared with those who
received vein grafts (P=0.003). They also observed that patients who
underwent bypass surgery after an initial failed angioplasty experi-
enced significantly worse amputation-free survival than those who
underwent bypass as the initial therapy (P=0.006), suggesting a real
potential downside to failed angioplasty in SLI.
& The primary recommendations from the BASIL trial perhaps are best
summarized by the authors in the following statement:
––“ … .SLI patients predicted to live more than 2 years, and with a
useable vein, should usually have bypass surgery first. This is
because the long term results of saphenous vein bypass surgery
are good, the rate of balloon angioplasty failure is high, and the
results of bypass surgery after failed balloon angioplasty are
significantly worse than for bypass surgery. However, patients
expected to live less than 2 years, and those without a useable
vein, should usually have balloon angioplasty first as they will
not survive to reap the longer term benefits of surgery and the
results of prosthetic bypass surgery are poor” [25•].
& There are several important limitations and controversies surround-
ing the application of the BASIL trial to current practice [28], yet this
study stands as a seminal RCT in the field of advanced limb ischemia
and a basis for the design of future trials.
Endovascular treatment of CLI
Standard procedure(s) Percutaneous angioplasty with or without adjunctive atherectomy
(mechanical or laser) and with or without adjunctive stenting.
Contraindications Relative: low estimated glomerular filtration rate, anatomically unfavorable
disease (common femoral artery lesion, extensive calcification, long segment
occlusions, severe popliteal and/or infrapopliteal disease).
Complications Thrombosis, embolization, blue toe syndrome, amputation, loss of surgical
target for bypass, access site complications (hemorrhage, pseudoaneurysm,
arteriovenous fistula), contrast nephropathy, and renal failure.
218 Vascular DiseaseSpecial points Techniques for endovascular treatment in the aortoiliac segment have become
more standardized and durability more consistent for TASC A to TASC C
disease (absence of a long segment occlusion for a complete description of
TASC criteria, please see Norgren et al. [10•]). Adequate treatment of the
common and profunda femoris arteries is of primary importance in CLI and
may require a hybrid or fully open approach (eg, femoral endarterectomy).
The role of covered stents in the aortoiliac segment is poorly defined. For
infrainguinal therapy, treatments and results are more heterogeneous. Several
devices are available for different lesion anatomies and technical circumstances
(eg, best approach for complete total occlusions), but little evidence is avail-
able to support one over the other. The benefit of routine use of nitinol stents
in the superficial femoral artery is still under debate [29]. No RCT data are
available demonstrating a benefit for the use of stents in popliteal or distal
vessels, or for the use of drug-eluting stents in lower-extremity vessels.
Cost/cost-effectiveness Several cost-effectiveness analyses have been performed comparing endo-
vascular therapy with open surgery in patients with CLI [24, 30]. Stoner et al.
[30] analyzed 381 femoropopliteal revascularization procedures (open by-
pass, n=183; endovascular, n=198) performed for claudication and CLI. In
the subset of patients with CLI, they reported an initial cost saving with
endovascular therapy ($7176 vs $13,277; PG0.001). However, during the
1-year study period, the patients who were treated with endovascular therapy
went on to require reinterventions, so this cost saving ultimately was lost at
1 year. Similarly, in the cost-effectiveness study that accompanied the BASIL
trial, no significant difference was seen, as the survival, hospital costs, and
health-related quality-of-life differences were minimal between the surgical
and endovascular study arms [24].
Surgery
& Open surgical bypass using autogenous vein traditionally has been the
gold-standard revascularization technique for patients with CLI due to
infrainguinal disease. However, this paradigm is evolving as new
endovascular technologies are being developed, used, and tested.
& Aortofemoral bypass using prosthetic conduit is a standard surgical
approach for extensive (eg, TASC D) aortoiliac disease or in the set-
ting of failed prior endovascular therapy. Expected operative mor-
tality is approximately 3% and durability is excellent (85%–90%
patency at 5 years and beyond).
& As noted earlier, adequate treatment of disease in the common and
deep femoral arteries (eg, endarterectomy and/or patch angioplasty)
at the time of either inflow or outflow reconstruction is of primary
importance for the long-term fate of the limb in CLI patients.
& Two RCTs examining novel CLI treatments (gene therapy [31] and
prostaglandin therapy [15]), a multicenter prospectively maintained
vascular registry [32], and one RCT comparing balloon angioplasty
with surgical bypass in patients with CLI (BASIL) [6] have provided a
wealth of high-quality outcomes data pertaining to vein bypass sur-
gery in patients with CLI. Several authors have used the information
contained in these surgical CLI datasets to further our understanding
of risk stratification and outcome prediction [22,33–39,40•],
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the associated outcomes [43], and resource utilization [41].
& Both BASIL [6] and PREVENT III (PIII) [31] challenge the nihilistic
paradigms about mortality rates in patients with CLI: 85% of PIII
patients survived beyond 1 year, and 70% of BASIL patients survived
longer than 2 years. These data suggest that CLI patients may be done
a tremendous disservice if the selection of their therapies is founded
on the concept that all CLI patients carry a substantial mortality risk
that warrants a short-term approach.
& A recent meta-analysis in patients with CLI undergoing infrainguinal
bypass demonstrated 5-year primary patency, secondary patency, and
limb salvage rates of 63%, 71%, and 78%, respectively [44]. Recently,
a working group under the auspices of the Society for Vascular Sur-
gery used pooled data from the PIII, BASIL, and Circulase studies to
develop expected outcomes for vein bypass surgery as the relevant
standard for comparing new devices. This group endorsed a set of
three safety and six efficacy objective performance goals for CLI based
on the pooled data from these surgical controls [40•]. These out-
comes are summarized in Table 2.
& Given the relative high-risk nature of the CLI patient population, as
well as the variety of available treatment options, the ability to use
Table 2. Suggested end point definitions for revascularization in critical limb ischemia and expected event
rates for open bypass surgery
a
End point Definition Event rate, % (95% CI)
Safety outcomes (30 d)
MACE Myocardial infarction, stroke, or death (any
cause)
6.2 (4.7–8.1)
MALE Above-ankle amputation of the index limb or
major reintervention (new bypass graft, jump/
interposition graft revision, or thrombectomy/
thrombolysis)
6.1 (4.6–7.9)
Amputation Above-ankle amputation of the index limb 1.9 (1.1–3.1)
Efficacy outcomes (1 y)
b
Perioperative death or MALE Perioperative death (30 d) or any MALE 76.9 (74.0–79.9)
Amputation-free survival Above-ankle amputation of the index limb or
death (any cause)
76.5 (73.7–79.5)
Reintervention, amputation, or stenosis Any reintervention, above-ankle amputation of
the index limb, or stenosis
46.5 (42.3–51.2)
Reintervention or amputation Any reintervention or above-ankle amputation of
the index limb
61.3 (58.0–64.9)
Limb salvage Freedom from above-ankle amputation 88.9 (86.7–91.1)
Survival Freedom from death (any cause) 85.7 (83.3–88.1)
aReported by the Society for Vascular Surgery Working Group for the development of objective performance goals for evaluating catheter-
based treatment [40]•. Data are pooled from prospective trials of vein bypass surgery in critical limb ischemia. Additional data are avail-
able at http://www.criticallimb.org/.
bAll rates are freedom from event.
MACE major adverse cardiovascular events, MALE major adverse limb events
220 Vascular Diseasepreprocedure variables to predict a given outcome has become in-
creasingly important. Several recent advances have been made in an
attempt to improve individual patient risk prediction at the time of
initial patient evaluation. The PIII CLI risk score is an easy-to-use risk
stratification model developed to predict amputation-free survival in
CLI patients undergoing open infrainguinal surgical bypass [45]. This
prediction tool was derived from the cohort of patients who under-
went autogenous vein bypass for CLI in the context of the PIII ran-
domized trial [46]. The PIII CLI risk score was then validated both
internally, using the trial cohort, and externally, using a multicenter
retrospective cohort of patients (total n=3286). In this study, the PIII
CLI risk score was found to be a highly reliable and simple tool for
stratifying CLI patients selected to undergo bypass surgery into low-,
medium-, and high-risk categories. At the time of a patient’s initial
presentation, five easily obtainable binary variables may be used to
provide patients and providers with a valid estimate of the likelihood
of amputation-free survival at 1 year after surgical revascularization.
These variables are dialysis dependency, tissue loss, advanced age,
advanced coronary artery disease, and low hematocrit. Numerous
key publications have identified predictors of specific outcomes in
case series of patients with CLI (Table 3). When looked at compre-
hensively, it becomes clear that patency and limb salvage outcomes
are, for the most part, linked to characteristics of the bypass graft (ie,
type of conduit) and the specific patient anatomy (ie, adequacy of
runoff score). In contrast, mortality and functional outcomes appear
to be more influenced by systemic comorbidities, preoperative
medications, and physiologic characteristics.
Surgical treatment of CLI
Standard procedure(s) Lower-extremity bypass grafting with or without femoral endarterectomy,
with or without adjunctive inflow (aortoiliac) treatment. The preferred graft
conduit for infrainguinal bypass is autogenous saphenous vein followed by
other autogenous venous conduits. Prosthetic or other nonautogenous
conduits should be considered significantly inferior secondary choices for
infrainguinal bypass in the CLI patient.
Contraindications Unacceptable surgical risk (eg, multiple comorbidities, advanced age), ad-
vanced tissue loss on weight-bearing surface, nonambulatory status, no
identifiable target vessel with runoff to ankle/foot. Relative contraindica-
tions: lack of adequate-quality autogenous vein conduit for infrageniculate
bypass, poor-quality target vessel, extensive infection or necrosis compro-
mising graft or vessel coverage.
Special points The inflow artery must have uncompromised hemodynamics, and arterial
outflow should be continuous to the ankle and foot. Vein graft origin (sa-
phenous vein is superior to all other venous conduits for infrainguinal re-
construction), graft diameter, and graft length all are key variables
influencing short-term and long-term patency [39]. Reversed, nonreversed,
or in situ vein configurations all are effective, and the choice is dictated
primarily by surgeon preference and anatomic circumstances.
Cost/cost-effectiveness See “Cost/cost-effectiveness” under “Endovascular treatment of CLI.”
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ischemia
Study Patients, n Study type Inclusion criterion Primary outcome
measure
Significant predictors
Robinson et al.,
2009 [67]
1646 Single-center
series
Bypass surgery for CLI
or claudication
Patency High-risk conduit, CLI,
smoking, age ≥65 y,
African American, female
Schanzer et al.,
2007 [39]
1404 Multicenter
RCT
Bypass surgery for CLI Patency Graft diameter, graft
length, non–single
segment GSV, popliteal
artery origin
Bradbury et al.,
2010 [23]
452 Multicenter
RCT
Bypass surgery and
angioplasty for SLI
Death Age, MI, stroke, tissue
loss, ankle pressure,
number of detectable
ankle pressures,
creatinine, smoking,
BMI, Bollinger score,
diabetes
Goodney et al.,
2010 [37]
2036 Multicenter
registry
Bypass surgery for CLI
or claudication
Death CHF, diabetes, CLI, absence
of single-segment GSV,
age 980 y, dialysis,
emergent procedure
Schanzer et al.,
2008 [22]
1404 Multicenter
RCT
Bypass surgery for CLI Death Statin therapy, age ≥75 y,
CAD, CKD stage 4/5,
tissue loss
Owens et al.,
2007 [68]
456 Single-center
series
Bypass surgery for CLI
or claudication
Death Age, CKD stage 4/5
Schanzer et al.,
2009 [36]
1166 Multicenter
registry
Bypass surgery for CLI Amputation-free
survival
Age ≥75 y, dialysis, tissue
loss,anemia,advancedCAD
Schanzer et al.,
2008 [45]
1404 Multicenter
RCT
Bypass surgery for CLI Amputation-free
survival
Age ≥75 y, dialysis, tissue
loss,anemia,advancedCAD
Biancari et al.,
2007 [69]
3925 Multicenter
registry
Bypass surgery for CLI Amputation-free
survival
Diabetes, CAD, foot
gangrene, urgent
operation
Goodney et al.,
2009 [34, 35]
2036 Multicenter
registry
Bypass surgery for CLI
or claudication
Amputation or loss
of secondary
patency
Age 40–49 y,
nonambulatory
preoperatively,
dialysis, diabetes, CLI,
composite vein grafts,
tarsal bypass target,
nursing home
preoperatively
Rossi et al.,
2003 [70]
468 Single-center
series
Bypass surgery for CLI
or claudication or
aneurysm
Amputation Gender, nonautologous
conduit, redo bypass
Toursarkissian
et al., 2002
[71]
124 Single-center
series
Bypass surgery for CLI
or claudication
Amputation Angiographic score, foot
score, diabetes
Alback et al.,
1998 [72]
132 Single-center
series
Bypass surgery for CLI
or claudication
Amputation “Ad hoc” grading system
of outflow arteries
BMI body mass index, CABG coronary artery bypass grafting, CAD coronary artery disease; CHF congestive heart failure, CKD chronic kidney
disease, CLI critical limb ischemia, GSV great saphenous vein, MI myocardial infarction, PCI percutaneous coronary intervention, RCT
?randomized controlled trial, SLI severe limb ischemia
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& Although hyperbaric therapy commonly is used for nonhealing
wounds, its efficacy has not yet been established in patients with CLI.
It may be of limited utility in patients in whom revascularization is
not technically feasible or for those who have failed all previous re-
vascularization attempts.
& Spinal cord stimulation has been proposed as an alternative to pri-
mary amputation in CLI patients with ischemic rest pain who are not
amenable to revascularization. This technique requires the implan-
tation of a subcutaneous pulse generator that stimulates electrodes at
the L3-L4 level. Although this technique has not enjoyed widespread
use, a recent meta-analysis did demonstrate significant pain reduc-
tion and an 11% reduced amputation rate compared with medical
therapy alone [47]. The role for this therapy presently is unclear.
& Intermittent pneumatic compression in patients with CLI is another
proposed therapy for augmenting distal arterial oxygen delivery in
Table 3. (continued)
Study Patients, n Study type Inclusion criterion Primary outcome
measure
Significant predictors
Simons et al.,
2010 [73]
1457 Multicenter
registry
Bypass surgery for CLI Clinical failure
(persistent
symptoms and/or
amputation)
despite bypass
patency
Dialysis, preoperative
ambulation with
assistance, history of
CABG or PCI
Goodney et al.,
2009 [34]
1400 Multicenter
registry
Bypass surgery for CLI
or claudication
Ambulatory failure Nonambulatory
preoperatively, CLI, age
≥70 y, postoperative MI,
postoperative
amputation
Taylor et al.,
2006 [74]
1000 Single-center
series
Bypass surgery for CLI Ambulatory
deterioration/
failure
Female, diabetes,
renal insufficiency,
dementia, homebound
preoperatively,
postoperative amputation
Nguyen et al.,
2006 [41]
1404 Multicenter
RCT
Bypass surgery for CLI Decreased
improvement in
quality of life
Diabetes, postoperative
graft-related event
Taylor et al.,
2006 [74]
1000 Single-center
series
Bypass surgery for CLI Non-independent
living
Age ≥70 y, ulceration,
previous stroke,
dementia, nonambulatory,
postoperative amputation
BMI body mass index, CABG coronary artery bypass grafting, CAD coronary artery disease; CHF congestive heart failure, CKD chronic kidney
disease, CLI critical limb ischemia, GSV great saphenous vein, MI myocardial infarction, PCI percutaneous coronary intervention, RCT
randomized controlled trial, SLI severe limb ischemia
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investigations have demonstrated increased muscular, collateral, and
skin blood flow in patients receiving compression therapy [48].
Furthermore, a small study comparing CLI patients receiving com-
pression therapy (n=24) with those receiving optimal medical
management (n=24) did demonstrate that compression therapy was
associated with improved wound healing, limb salvage, and trans-
cutaneous oximetry [49]. Larger studies are needed to determine a
role for intermittent pneumatic compression in CLI.
Emerging therapies
& NewrevascularizationstrategiesforCLIpatientsnotamenabletoeither
endovascular or surgical revascularization are being explored. Based on
an increased mechanistic understanding of angiogenesis and arterio-
genesis,noveltherapeuticapproachesincludingmolecular,genetic,and
cell-based treatments have entered the clinical trial phase [50].
& In the PIII study, published in 2006, 1404 CLI patients undergoing
bypass surgery were randomly assigned to receive edifoligide (a DNA
molecule that inhibits cell cycle gene expression and was hypothe-
sized to reduce neointimal hyperplasia) or placebo. The study treat-
ment was found to confer no benefit or harm on either the primary
study end point of time to index graft reintervention or major am-
putation or the secondary end points of all-cause graft failure, sig-
nificant graft stenosis, amputation/reintervention-free survival, and
nontechnical primary graft patency [31].
& Several gene therapy RCTs using hepatocyte growth factor [51], fi-
broblast growth factor [52], and vascular endothelial growth factor
[53–55] have been carried out in an attempt to activate the angio-
genesis pathway. Preliminary data from these studies suggest limited
gains. In one study, the authors demonstrated improvement in their
primary study end point (improvement in the angiographic indices
3 months after vascular endothelial growth factor gene transfer) [54].
In a phase 2 double-blind RCT, intramuscular injection of hepatocyte
growth factor plasmid in 104 CLI patients demonstrated safety, and
transcutaneous oxygen levels increased at 6 months in the high-dose
group [51]. Nikol et al. [52] reported a European phase 1/2 RCT
examining a plasmid-based fibroblast growth factor gene delivery
approach in 125 CLI patients; there was no significant difference in
the primary end point (ulcer healing), but amputation-free survival
was improved. Larger RCTs are required in the field, but significant
challenges in study design, recruitment, and costs have slowed
progress in this area.
& Cell therapy is a regenerative medical approach for CLI aimed at
enhancing angiogenesis. Cell therapy trials to date have included
relatively few patients compared with gene therapy trials. Nonethe-
less, the preliminary findings are encouraging. Autologous cells of
various sources (eg, peripheral blood, bone marrow, adipose tissue)
224 Vascular Diseaseand cell type (endothelial progenitors, mesenchymal stem cells, pe-
ripheral blood mononuclear cells) have been used in phase 1/2
investigations in CLI. Bone marrow mononuclear cells injected into
the gastrocnemius [56] and intra-arterial infusion of circulating
blood-derived progenitor cells [57] both have been associated with
improvements in prespecified primary end points. There are several
ongoing studies in this area.
& Drug-eluting balloons and stents have undergone limited evaluation
in the lower-extremity circulation to date. Recent reports of superfi-
cial femoral artery angioplasty using a paclitaxel-coated balloon have
shown encouraging results [58–60], and further trials are planned in
the CLI population. Drug-eluting stents are being evaluated in the
femoral and infrapopliteal arteries. No data are available yet on the
utility of these technologies for CLI.
& Bioresorbable stents offer the potential to prevent recoil post an-
gioplasty, improve remodeling, and eliminate the long-term in-
flammatory response to the implant. This technology is in an early
stage. An initial trial of a bioresorbable stent for infrapopliteal dis-
ease in CLI patients failed to show any significant benefit [61].
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